** Scholar Rock's shares SRRK.O up 3.4% premarket
** Co says U.S. FDA accepts SRRK's drug, apitegromab, for priority review with a decision expected by Sept 22; EU's medicines regulator has also accepted drug for review
** Co's drug treats spinal muscular atrophy, which stops production of a protein necessary for neuromuscular development and leaves children too weak to walk, talk and swallow
** In a late-stage study, patients given apitegromab saw better improvement in motor function than those given a placebo
** As of last close, SRRK up nearly 17% so far this year
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.